A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients' brain tumors.
Powerful technique details brain tumors resiliency cornell.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cornell.edu Daily Mail and Mail on Sunday newspapers.
Candidate Immunotherapy Target Identified for Brain Cancer, Possibly Other Tumors
February 16, 2021
Source: National Cancer Institute; creator Rhoda Baer, photographer
Scientists at Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard, reported the discovery of a potential new target for immunotherapy of malignant brain tumors. The team used single-cell RNA sequencing (RNA-seq) to study gene expression and the clonal landscape of tumor-infiltrating T cells across more than 30 patients with diffuse gliomas and glioblastoma. Their work indicated that the immune cell surface receptor, CD161, suppresses the cancer-fighting activity of immune T cells, and is activated by its ligand, CLEC2D, on tumor cells and immune-suppressing cells in the brain. Their studies showed that genetically deleting the KLRB1 that codes for CD161, or using antibodies to block CD161, increased T cell-mediated killing of glioma cells in vitro and anti-tumor
Scientists discover new immunotherapy target for malignant brain tumors
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body s immune system. The discovery, reported in the journal
CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
Scientists from Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard said the target they identified is a molecule that suppresses the cancer-fighting activity of immune T cells, the white blood cells that seek out and destroy virus-infected cells and tumor cells.